Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Med.

Sec. Hematology

Volume 12 - 2025 | doi: 10.3389/fmed.2025.1606953

This article is part of the Research TopicMolecular Characterisation of Autoimmune DiseasesView all 12 articles

Combined FCGR2A (131H/R) and FCGR3A (158F/V) genotypes and their gender-specific association with chronic and refractory immune thrombocytopenia in Palestinian children

Provisionally accepted
Khitam  AmerKhitam Amer1Johnny  AmerJohnny Amer1*Adham  Abu TahaAdham Abu Taha1Wisam  BakerWisam Baker2Awad  AbuhamedAwad Abuhamed3Ahmad  SalhabAhmad Salhab1
  • 1An-Najah National University, Nablus, Palestine
  • 2Martyr Dr. Khalil Suleiman Governmental Hospital, Jenin, Palestine
  • 3Rafidia Surgical Hospital, Nablus, Palestine

The final, formatted version of the article will be published soon.

Background: Immune thrombocytopenia (ITP) is a common pediatric autoimmune disorder characterized by low platelet counts and heightened bleeding risk. Fc gamma receptors (FcγRs), particularly FCGR2A (131H/R) and FCGR3A (158F/V), mediate immune responses and may influence ITP susceptibility and progression. Gender-related genetic variation has been proposed but remains underexplored, particularly in Middle Eastern pediatric populations. This study aimed to perform an exploratory assessment of the prevalence and potential clinical relevance of FCGR2A and FCGR3A polymorphisms, including gender-based tendencies, in Palestinian children with ITP. Methods: A multicenter case-control study included 40 proven pediatric ITP patients (20 males, 20 females; mean age 6.76 ± 4.13 years) and 80 age- and sex-matched healthy controls. Genotyping was performed using PCR-RFLP and nested PCR. Genotype frequencies were correlated with disease phenotype and sex. Results: No statistically significant differences in genotype distributions were observed between ITP cases and controls for either FCGR2A (HH: 17.5%, HR: 62.5%, RR: 20.0%) or FCGR3A (FF: 25.0%, FV: 55.0%, VV: 20.0%) (p > 0.05). However, a secondary, exploratory analysis for gender-specific trends yielded noteworthy observations: FCGR2A-HH was numerically more frequent in male ITP patients (57.4%) than in females (42.8%), while HR was lower in males (48% vs. 52%). Similarly, FCGR3A-VV occurred in 62.5% of male ITP patients versus 37.5% in females. Furthermore, the combined HR/FV genotype (32.5%) showed a non-significant trend of association with chronic ITP (69.2%), while the VV/HH genotype, although rare (5%), was linked to 50% of refractory presentations. Conclusion: This exploratory study found no statistically significant association between FCGR2A and FCGR3A polymorphisms and overall ITP susceptibility in the full cohort. However, the observed trends, particularly the distinct gender-based distribution of specific genotypes and the association of combined genotypes with chronic and refractory disease, suggest that these genetic markers may play a role in disease progression. Further investigation in a larger, appropriately powered study is warranted to validate these findings and to understand their potential to guide personalized treatment approaches for pediatric ITP.

Keywords: immune thrombocytopenia, Fc gamma receptors (FcγRs), FCGR2A (131H/R), FCGR3A (158F/V), polymorphisms

Received: 06 Apr 2025; Accepted: 06 Oct 2025.

Copyright: © 2025 Amer, Amer, Taha, Baker, Abuhamed and Salhab. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Johnny Amer, j.amer@najah.edu

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.